Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 9/20 | 0.43 |
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | PTGES | O14684 | 3/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
| ▸ | ILK | Q13418 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL793642 | 0.94 | TYK2 (0.46) | TYK2JAK2PSMB8ADORA3ADORA2A | |
| SCHEMBL792091 | 0.87 | TYK2 (0.48) | TYK2JAK2PSMB8ADORA2A | |
| SCHEMBL793202 | 0.86 | TYK2 (0.41) | TYK2JAK2PSMB8ADORA3ADORA2A | |
| SCHEMBL793584 | 0.86 | TYK2 (0.44) | TYK2JAK2FGFR1SRCLMNA | |
| SCHEMBL792546 | 0.83 | TYK2 (0.43) | TYK2 | |
| SCHEMBL791822 | 0.81 | TYK2 (0.49) | TYK2JAK2PTGESFGFR1SRC | |
| SCHEMBL792565 | 0.81 | TYK2 (0.47) | TYK2JAK2ADORA3ADORA2AADORA1 | |
| SCHEMBL792203 | 0.80 | TYK2 (0.47) | TYK2PSMB8ADORA3ADORA2AADORA1 | |
| SCHEMBL792706 | 0.80 | TYK2 (0.61) | TYK2PSMB8 | |
| SCHEMBL792619 | 0.76 | TYK2 (0.55) | TYK2JAK2FGFR1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140171408-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-8697708-B2 | Azabenzothiazole compounds, compositions and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2014-04-15 | — | — | US | disclosed |
| EP-2616072-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| US-20120202788-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
| WO-2012035039-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171408-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F12, CHRM1, NPY1R | TYK2 229/4885JAK2 544/4885PSMB8 2354/4885 |
| US-20120202788-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F12, CHRM1, NPY1R | TYK2 229/4885JAK2 544/4885PSMB8 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.